1865886804
Longevity.Technology UNLOCKED

Advertise on podcast: Longevity.Technology UNLOCKED

Rating
★★★★★
5
from
4 reviews
This podcast has
81 episodes
Language
English
Explicit
No
Date created
2026/01/02
Latest episode
2026/11/09
Average duration
39 min.
Release period
6 days

Description

Longevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living. 🎙 Mondays: In-depth conversations with scientists, founders, investors, operators, and elite performers shaping the longevity ecosystem. 🧠 Fridays: A sharp weekly round-up of the biggest stories, trends, and insights from across the longevity space. If you’re curious about the future of health, performance, and lifespan, this is where it gets UNLOCKED.

Unlock Longevity.Technology UNLOCKED podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Longevity.Technology UNLOCKED podcast


Can Biological Age Clocks Show Which Longevity Strategies Work?
2026/11/09
Guest: Christin Glorioso, MD. Ph.D. Creator of the Younger Biological Aging Contest, Founder & CEO of NeuroAge Therapeutics LinkedIn: https://www.linkedin.com/in/christin-glorioso-md-phd-39627719/ Website: https://www.neuroagetx.com/authors/christin-glorioso Ryan Smith Co-Founder and Director of Research & Development at TruDiagnostic LinkedIn: https://www.linkedin.com/in/ryan-smith-lexington-ky/ Website: https://www.trudiagnostic.com/ _______________ What if measuring biological age could show which interventions actually improve health? Phil Newman sits down with Dr. Christin Glorioso, physician, neuroscientist and founder of NeuroAge and Longevity Global, and Ryan Smith of True Diagnostic to explore the Younger biological aging contest and the future of aging biomarkers. They explain how its six-month challenge combines DNA methylation, proteomics, RNA and glycan clocks with brain imaging and physical-function tests. The resulting data could help compare biomarkers, personalize interventions and strengthen evidence for clinical trials. They also discuss brain health, GLP-1 research, surrogate endpoints and how AI could accelerate biomarker validation. In this episode, you'll learn: - What Younger measures - How multi-omics can refine biological age testing - Which lifestyle factors show promising signals - How brain data can guide personalized recommendations - What biomarkers need before regulators can rely on them This episode connects emerging aging science with practical routes toward personalized, preventative healthcare. Subscribe for weekly episodes on longevity science, preventative medicine and healthier, longer lives. _______________ Host:  Phil Newman: https://qrco.de/bgXpNY
Why the Secret to Human Longevity May Be Hidden in Animals
2026/11/02
Guest: Dr. Steven N. Austad, Ph.D. Distinguished Professor of Biology at University of Alabama at Birmingham LinkedIn: https://www.linkedin.com/in/steven-austad-b31b5090/ Website: https://www.uab.edu/cas/biology/people/faculty/steven-n-austad Alan Richardson, Ph.D. Professor of Biochemistry & Physiology at University of Oklahoma Health Sciences Center LinkedIn: https://www.linkedin.com/in/arlan-richardson-357977b3/ Website: https://medicine.ouhsc.edu/directory/details/arlan-richardson-phd-1 _______________ What if some of the best clues to human longevity are already hidden across the animal kingdom? Phil Newman sits down with aging researchers Steven Austad and Arlan Richardson to explore what decades of animal research can teach us about extending human healthspan. Together they explain why mice remain valuable but imperfect models, and how bowhead whales, naked mole rats, bats and 500-year-old clams reveal different biological routes to longevity. They also discuss genetically diverse rats, dietary restriction, fasting and the challenge of translating laboratory discoveries into humans. In this episode, you'll learn: - Why mice alone cannot model human aging - What exceptionally long-lived species reveal - Why genetic diversity matters - How fasting differs from chronic calorie restriction - Why GLP-1s, proteomics and AI could accelerate longevity research If you want to understand where longevity research goes next, this episode connects evolutionary biology with emerging human therapeutics. Subscribe for weekly episodes that explore longevity science, preventative med _______________ Host:  Phil Newman: https://qrco.de/bgXpNY
Why The $101 Million XPRIZE Could Redefine Human Healthspan
2026/10/26
Guest: Jamie Justice, Ph.D. Executive Director, XPRIZE Healthspan and Vice President of the Health Domain at XPRIZE Foundation LinkedIn: https://www.linkedin.com/in/jamie-justice-ph-d-6b933146/ Website: https://www.xprize.org/ Steven R. Cummings, MD Executive Director at S.F. Coordinating Center (SFCC) in the CPMC Research Institute LinkedIn: https://www.linkedin.com/in/steve-cummings-71668514a/ Website: https://www.xprize.org/people/steve-cummings _______________ What if the breakthrough longevity needs isn’t another intervention, but a better way to prove what works? Phil Newman sits down with XPRIZE Healthspan director Jamie Justice and judging chair Professor Steven Cummings to explore the $101 million competition. Together they explain why muscle, cognitive and immune function form its evidence framework, and how one-year trials could help model longer-term healthspan gains. From repurposed drugs to gene therapies, finalists must demonstrate measurable effects under common standards. They also discuss FDA pathways, scalability, safety and prevention versus reversal. In this episode, you'll learn: - How finalists are judged - Why function matters beyond biomarkers - How trials model 10–20 years of decline - Why scalability matters - Why safety could determine success If you want to understand how longevity interventions could become credible medicine, this episode connects rigorous trials with real-world healthspan. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. _______________ Host:  Phil Newman: https://qrco.de/bgXpNY
Could Intrinsic Capacity Become the Endpoint for Longevity Drugs?
2026/10/19
Sponsor: Sooo.me Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging. See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off. Link: https://sooo.me/?ref=LTUNLOCKED ---------- Guests: John Beard Irene Diamond Professor and Director International Longevity Center USA, Columbia University LinkedIn: https://www.linkedin.com/in/john-beard-987b801b/ Website: https://www.publichealth.columbia.edu/profile/john-beard-mbbs ---------- What if the way we measure health is holding back the science of aging? Phil Newman sits down with Dr. John Beard, Irene Diamond Professor and Director of the International Longevity Centre USA at Columbia University, to explore intrinsic capacity – measuring health through what people can actually be and do rather than the diseases they have. Together they unpack the five domains of intrinsic capacity and why functional measures could give researchers a more continuous picture of aging. From simple chair-rise and hearing tests to clinical trial endpoints, biomarkers and wearables, Beard explains both the potential and the gaps that remain. They also discuss why “70 is the new 60,” the difference between prevention and health promotion, why some longevity clinics are ahead of the evidence, and how intrinsic capacity could reshape healthcare funding and drug development. In this episode, you'll learn: - Why disease alone is an incomplete measure of aging - How intrinsic capacity measures cognitive, locomotive, psychological, sensory and vitality domains - Why better standardized measures could help shorten aging intervention trials - How early-life health can influence capacity decades later - Why healthcare systems could eventually reward improvements in health rather than throughput If you want to understand how measuring function could change geroscience, clinical trials and healthcare itself, this episode connects aging biology with practical measures of how well people actually live. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. ---------- Host:  Phil Newman: https://qrco.de/bgXpNY
BPC-157, GLP-1s and the New Peptide Gold Rush
2026/10/05
Sponsor: Sooo.me Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging. See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off. Link: https://sooo.me/?ref=LTUNLOCKED ---------- Guests: Fady Hannah-Shmouni, MD FRCPC Founder & CEO of Hormonaly.ai LinkedIn: https://www.linkedin.com/in/fady-hannah-shmouni/ Website: https://shmouni.com/ Koehl Robinson Founder & CEO of Celia Health LinkedIn: https://www.linkedin.com/in/koehlrobinson/ Website: https://www.celia-rx.com/ ---------- What happens when demand for peptide therapies starts moving faster than the science, regulation and clinical infrastructure surrounding them? Phil Newman sits down with Dr. Fady Hannah-Shmouni and Koehl Robinson to explore one of longevity medicine’s fastest-moving areas: peptides. From evidence-backed GLP-1 drugs to compounds such as BPC-157 with far more limited human evidence, they examine where the science is strong, where uncertainty remains and what patients should understand before entering this rapidly expanding market. Together they explore how a cleaner peptide supply chain could work, why testing and clinical oversight matter, and how real-world data could help fill some of the evidence gaps where randomized controlled trials remain limited. They also discuss personalized prescribing, biomarker monitoring, AI and what responsible peptide medicine could look like as the industry matures. In this episode, you'll learn: - Why Fady describes GLP-1s as the standout peptide class, with potential effects extending beyond weight management into appetite and other reward-related behaviors. - Why compounds such as BPC-157 still have major evidence gaps, with much of the published literature remaining preclinical rather than based on high-quality randomized human trials. - How Koehl says Celia RX is building a US-based supply chain with multiple stages of testing, third-party analysis and batch testing to improve transparency around peptide sourcing. - How lab, genomic and epigenetic testing could be combined with consultations and follow-up monitoring to move peptide prescribing toward a more personalized model. - Why AI and real-world multi-omic data could help clinicians make sense of a fragmented evidence base while researchers continue building stronger clinical evidence. The conversation also tackles the uncomfortable reality of the peptide “gray market.” As consumer demand grows, products can vary significantly in sourcing, testing and clinical oversight. Fady and Koehl discuss why transparency around evidence and risk matters, and why better infrastructure may be essential if peptide medicine is going to move further into mainstream healthcare. If you want to understand where peptide medicine stands today – from established therapies to experimental compounds – this episode separates the growing enthusiasm from the evidence still needed to support it. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
Are Your Supplements Actually Doing Anything?
2026/09/28
Sponsor: Sooo.me Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging. See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off. Link: https://sooo.me/?ref=LTUNLOCKED ---------- Guests: Dr. Christopher Shade Founder and CEO of Quicksilver Scientific LinkedIn: https://www.linkedin.com/in/dr-christopher-shade-b5a44413/ Website: https://www.quicksilverscientific.com/ ---------- What if the biggest problem with your supplements isn’t what you take, but how much actually reaches your cells? Phil Newman sits down with Dr. Christopher Shade, founder and CEO of Quicksilver Scientific, to explore the science of supplement absorption, detoxification and next-generation nutrient delivery. Together they unpack why absorption can vary dramatically between compounds, how liposomal and nanoemulsion systems are designed to improve bioavailability, and why Shade believes detox requires more than short-term cleanses. From his “push-catch” approach to oral peptides, GLP-1 support and NAD+, the conversation examines how delivery could change the way longevity interventions are designed. In this episode, you'll learn: - Why Shade says detoxification needs to address cellular mobilization, liver and bile pathways, and elimination rather than relying on short-term “detox teas” or juice cleanses. - How absorption can vary dramatically between supplements, with Shade citing less than 1% absorption for standard berberine and reporting a 300-fold increase in curcumin absorption using his company’s delivery technology. - Why Quicksilver is exploring oral liposomal versions of peptides including BPC-157, KPV, TB-500, GHK-Cu and epitalin, and why Shade says dose equivalence matters when comparing oral delivery with injections. - Why coming off GLP-1 drugs may require more than simply stopping treatment, with nutrition, exercise and metabolic health forming part of the wider conversation. - How Shade sees the future moving toward personalized supplement stacks guided by biomarkers, genomics and individual response, rather than simply taking more products. The conversation also tackles the increasingly crowded supplement market and the challenge consumers face when trying to distinguish meaningful delivery science from marketing claims. Shade argues that pharmacokinetic data, manufacturing quality and measurable absorption should matter more than simply seeing “liposomal” written on a label. If you want to understand why longevity may depend not only on what you take, but whether your body can actually use it, this episode connects chemistry, supplementation and emerging delivery technologies with a more measured approach to optimizing health. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
Longevity Biotech’s $617Billion Opportunity | Longevity News Roundup — Week 39, 2026
2026/09/25
Sponsored by: MuseCell Innovations MuseCell Innovations is the exclusive global licensor of Dezawa MuseCells®, a naturally occurring, pluripotent-like stem cell platform discovered by Professor Mari Dezawa at Tohoku University. Built on more than 15 years of peer-reviewed research, the company focuses on advancing regenerative medicine across longevity, disease treatment, performance and aesthetics through authenticated cell technology and licensed manufacturing methods. Read more about it here: https://bit.ly/4y0rhpW Free Report: https://longevity.technology/data/report/longevity-biotech-report-2026/ Market Model Explorer: https://longevity.technology/data/dashboard-biotech-explorer-tam-and-value/ ---------- In this special Longevity News Roundup, Phil Newman explores the findings behind Longevity.Technology’s latest Longevity Biotech Report, examining investment, market potential, regulation, global competition and regenerative platforms. - More than $30 billion has flowed into longevity biotech in under two years, with investment increasingly concentrated in larger deals and companies with credible clinical programmes. - The report forecasts a potential $617 billion annual global market by 2045, based on assumptions around pricing, population uptake, prevention and the emergence of new healthcare budgets. - The existing pipeline is already projected toward $230 billion in annual revenue through conventional disease indications, with a further $173 billion in potential gerotherapeutic upside if regulatory pathways develop. - Regulatory change could be critical, with ARPA-H’s PROSPR programme, biomarker qualification and future legislative frameworks potentially helping move ageing-related interventions toward multi-disease approval pathways. - China is becoming an increasingly important force, with 59 China-headquartered companies in the tracked cohort raising $16.9 billion and reportedly moving clinical programmes 50–70% faster than US counterparts. - Regenerative platforms such as MuseCell Innovations could offer a more scalable development model, allowing validated platforms to support multiple disease programmes while still requiring indication-specific clinical evidence and regulatory approval. News & References: - $617 billion longevity biotech market takes shape → https://longevity.technology/news/617-billion-longevity-biotech-market-takes-shape/ - What is longevity biotech really worth? → https://longevity.technology/news/what-is-longevity-biotech-really-worth/ - Longevity biotech’s 100x question → https://longevity.technology/news/longevity-biotechs-100x-question/ ---------- Host: Phil Newman: https://qrco.de/bgXpNY
Menopause Changes the Brain More Than We Realised
2026/09/21
Sponsor: Sooo.me Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging. See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off. Link: https://sooo.me/?ref=LTUNLOCKED ---------- Guests:  Elizabeth Poynor, MD, Ph.D Chair of Women's Health & Gynecology of Atria Health Institute LinkedIn: https://www.linkedin.com/in/elizabeth-poynor-md-phd-390491177/ Website: https://www.atria.org/doctors/ David Dodick, MD Chief Medical Officer of Atria Health Institute LinkedIn: https://www.linkedin.com/in/david-dodick-93a107269/ Website: https://www.atria.org/doctors/ ---------- What if protecting women’s brains from dementia needs to begin decades before symptoms appear? Phil Newman sits down with Dr. Elizabeth Poyner and Dr. David Dodick to explore why midlife should be viewed not simply as a reproductive transition, but as a major neurological, hormonal and cardiometabolic one. Together, they examine how fluctuating estrogen during perimenopause can influence brain energetics, sleep, memory and executive function – often before women even recognize they are approaching menopause. Together they explain how fluctuating estrogen can affect brain energetics, why migraine can signal hormonal change, and how insulin resistance, visceral fat and chronic stress can compound brain-health risks. They also unpack the critical window for hormone therapy and why prevention needs a personalized approach. In this episode, you'll learn: Why almost two out of every three Americans living with Alzheimer’s are women, and why longevity alone may not explain the difference.How estrogen fluctuations can affect glucose metabolism, mitochondrial function, sleep and cognitive performance during midlife.Why migraine affects women around three times more often than men and can worsen dramatically during perimenopause.Why optimizing 14 modifiable risk factors could prevent at least 45% of dementia, and why exercise may be one of the most powerful interventions available.How combining hormonal, neurological, metabolic and cardiovascular assessments could enable a more personalized approach to protecting women’s long-term brain health. If you want to understand women’s brain aging, this episode connects hormones, metabolism and neuroscience with practical insights for protecting long-term health. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
Can You Make Your Brain 5 Years Younger?
2026/09/14
Guests: Paola Telfer Founder and CEO of Sens.ai LinkedIn: www.linkedin.com/in/paolatelfer/ Website: sens.ai/ Eric Verdin, MD President and CEO of the Buck Institute for Research on Aging LinkedIn: www.linkedin.com/in/eric-verdin-md/ Website: www.buckinstitute.org/ ---------- What if we could track brain aging through function, not just structure? Phil Newman sits down with Paola Telfer, founder and CEO of Sens.ai, and Eric Verdin, president and CEO of the Buck Institute for Research on Aging, to explore BrainYears™, a functional brain age clock designed to measure how the brain performs as it ages. Together they explain how 643 EEG, response and performance variables were analyzed using machine learning to build the BrainYears™ model. They discuss why brain function could complement MRI, retinal, proteomic and epigenetic clocks, and how data collected from people aged 13 to their late 80s helped build the model. The conversation also examines a reported 5.18-year reduction in BrainYears™ following a two-month intervention, while stressing that this early finding still requires prospective, placebo-controlled validation. They also explore neurofeedback, HRV biofeedback and transcranial photobiomodulation, the potential role of BrainYears™ in clinical practice, and Eric’s vision for a scientifically rigorous space between conventional medicine and consumer wellness. In this episode, you’ll learn: Why functional brain aging may be a missing dimension in current aging clocksHow 643 EEG, response and performance variables were narrowed down using machine learning to create the BrainYears™ modelWhy tracking trajectory over time may be more informative than a single biological age scoreWhat the early intervention data showing a reported 5.18-year BrainYears™ reduction actually tells usWhy future validation needs to compare BrainYears™ with MRI-based clocks, proteomics and other measures of brain aging If you want to understand how brain aging could become measurable, trackable and potentially modifiable earlier in life, this episode explores the science, technology and validation challenges shaping that future. Subscribe for weekly episodes exploring longevity science, preventative medicine and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
The Smart Ring Accuracy Crisis | Longevity News Roundup — Week 37, 2026
2026/09/11
In this week’s Longevity News Roundup, Phil Newman examines Oura’s IPO and sleep suit, movement context in dementia, dog gene therapy, Rentosertib biological clocks, and women's health. ŌURA filed for a $16 billion IPO on Nasdaq under ticker Oura, seeking to raise up to $3 billion. Simultaneously, the smart ring company is defending its sleep stage tracking accuracy in a California class action lawsuit alleging its metrics are no better than a coin flip.A 74-study review of 4.2 million people showed leisure movement lowered dementia risk by 24%, while physically demanding jobs increased risk by 20%. This highlights how movement context and recovery matter far more than basic step counts.GenFlow Biosciences reported that its SLAB trial testing SIRT6 gene therapy in 24 aged beagles met its primary endpoint. Treated dogs demonstrated reduced biological age on the Grim methylation clock alongside secondary functional gains.Insilico Medicine published a Phase 2a trial analysis revealing its AI-designed IPF drug Rentosertib reduced predicted biological age. Across six proteomic clocks, patients taking 30 mg twice daily showed three to four years of age reduction.Biograph launched a dedicated women's preventative health program integrated into its concierge membership tiers. The program combines hormone testing, personalized risk assessments, and life-stage care spanning perimenopause, menopause, and cardiovascular health. ---------- News & References: ‘Biograph builds dedicated women’s preventive health arm → https://longevity.technology/news/biograph-builds-dedicated-womens-preventive-health-arm/Rentosertib puts aging clocks to the clinical test → https://longevity.technology/news/rentosertib-puts-aging-clocks-to-the-clinical-test/Genflow Biosciences trial meets primary endpoint in aged dogs → https://longevity.technology/news/genflow-biosciences-trial-meets-primary-endpoint-in-aged-dogs/Study shows the way you move matters more than how often → https://longevity.technology/news/study-shows-the-way-you-move-matters-more-than-how-often/Smart ring maker Oura prepares for US IPO at up to $3b raise → https://longevity.technology/news/smart-ring-maker-oura-prepares-for-u-s-ipo-at-up-to-3b-raise/ŌURA defends its sleep science amid class-action lawsuit → https://longevity.technology/news/oura-defends-its-sleep-science-amid-class-action-lawsuit/ ---------- Host:Phil Newman: https://qrco.de/bgXpNY
Will AI Make Death Optional?
2026/09/07
What would have to be true for AI to genuinely change the trajectory of human aging? The answer is more complicated than simply discovering an “anti-aging drug.” AI is already compressing parts of drug discovery, with one AI-designed candidate reaching Phase 2 trials in under 30 months, while new biological aging clocks could allow researchers to measure changes in months rather than decades. But aging is not a single disease. It involves interconnected processes including cellular senescence, mitochondrial dysfunction, immune changes, DNA damage, and loss of biological coordination. AI can search faster, but it cannot remove the underlying biological trade-offs or eliminate the need for long-term human safety data. Phil examines what longevity escape velocity actually means, why skepticism remains essential, and whether AI can accelerate progress quickly enough to matter within our own lifetimes. In this episode, you’ll learn: How AI is compressing drug discovery timelines and what that could mean for longevity research. Why biological aging clocks could become critical tools for testing interventions faster. Why aging is fundamentally more complex than targeting a single disease pathway. How cellular reprogramming illustrates both the promise and risks of manipulating aging biology. Why progression from Phase 1 to Phase 2 may be a more useful scorecard than predictions about longevity escape velocity. If you want to understand what AI can realistically change about the pace of longevity research, this episode connects faster drug discovery and biological aging measurement with the deeper challenges of intervening in a complex, interconnected aging process. It explores where the science is genuinely moving forward, where the biggest limitations remain, and what could determine whether today’s advances translate into meaningful healthspan gains. Subscribe for more Longevity Bites, where Phil Newman breaks down the science, ideas, and emerging technologies shaping the future of human longevity ---------- Host: Phil Newman: https://qrco.de/bgXpNY
The $820 Million Bet to Transform Hair Loss Treatment | Longevity News Roundup - Week 36, 2026
2026/09/04
In this week’s Longevity News Roundup, Phil Newman examines the developments reshaping longevity and healthspan, from a major biotech investment in hair loss to AI-driven drug repurposing, the industry’s communication challenge, biological-age testing at population scale, and the push to manufacture regenerative cell therapies in the US. Veradermics has built an $820 million war chest to advance VDPHL01, an extended-release oral formulation of minoxidil for male and female pattern hair loss. Phase 3 data for men are expected in the second half of 2026, with topline results from the women’s Phase 2/3 trial expected in the first half of 2027.THPharm and Insilico Medicine are using AI to investigate new applications for THP-001, already in global Phase 3 trials. PandaOmics is analysing 16 datasets covering 269 samples to explore potential applications in heart failure, fatty liver disease and obesity.HEALTH’s new Longevity Insights Report, based on responses from 1,000 Americans, suggests consumers are more interested in staying healthy, energetic and independent than simply extending lifespan. Humanity and Quest Diagnostics are making biological-age analysis available through Quest’s direct-to-consumer testing platform for $29. The bigger opportunity may be turning biological age into a repeatable health metric that encourages prevention and measurable improvements over time.Celularity and MuseCell Innovations are establishing US manufacturing for Dezawa MuseCells, alongside derived products including MuseExosomes and MuseSecretome. The collaboration addresses one of regenerative medicine’s biggest challenges: producing specialist cell therapies consistently and at scale. News & References: ‘Veradermics builds $820m war chest for oral hair loss pill → https://longevity.technology/news/veradermics-builds-820m-war-chest-for-oral-hair-loss-pill/AI hunts new uses for Phase 3 metabolic drug → https://longevity.technology/news/ai-hunts-new-uses-for-phase-3-metabolic-drug/New survey reveals what Americans really want from longevity → https://longevity.technology/news/new-survey-reveals-what-americans-really-want-from-longevity/Quest, Humanity bring biological age test to 2,000 US locations→ https://longevity.technology/news/quest-humanity-bring-biological-age-test-to-2000-us-locations/Celularity, MuseCell Innovations to build US Dezawa MuseCell plant → https://longevity.technology/news/celularity-musecell-innovations-to-build-us-dezawa-musecell-plant/---------- Host:Phil Newman: https://qrco.de/bgXpNY
Are Longevity Clinics Actually Evidence-Based?
2026/08/31
Guest: Joanna Bensz Founder & CEO of Longevity Center and Longevity Academy LinkedIn: https://www.linkedin.com/in/joanna-bensz-205b315/ Website: https://longevity-academy.com/, https://longevity-center.eu/ ---------- What happens when longevity becomes a global industry before the medical system has agreed on what good longevity medicine actually looks like? Phil Newman sits down with Joanna Bensz, entrepreneur, founder of the International Institute of Longevity, Longevity Academy and Round Table of Longevity Clinics, to explore how a rapidly expanding sector can develop credible standards while keeping pace with commercialization. They discuss the growth of longevity clinics, from premium destinations and telehealth platforms to sports centres and preventive health providers, and why Joanna estimates that only around 20% of the clinics she knows genuinely focus on diagnostics and interventions. The conversation examines peptides, biological-age testing, clinical education and the need for protocols that connect biomarkers with appropriate interventions rather than simply adding more treatments. Joanna explains how Longevity Academy evolved from an internal doctor-training programme into an educational platform for clinicians, drawing on real-world clinic experience, biomarkers, testing and treatment decisions. The episode goes beyond the clinic itself, examining the growing role of sports centres, retreats, AI, mental health, nervous-system regulation, nutrition and family health. Joanna argues that longevity should not be reduced to peptides or expensive interventions, but should include the everyday environments and behaviours that shape health across the lifespan. In this episode, you’ll learn: Why rapid commercialization could outpace the development of clinical standardsWhy Joanna estimates only around 20% of longevity clinics genuinely focus on diagnostics and interventionsHow Longevity Academy is helping doctors bridge gaps in conventional medical education Why peptides illustrate the regulatory differences between the US and Europe Why longevity clinics need doctors, nutritionists, psychologists, coaches and other specialists working together - How biomarkers can be used to track changes before and after interventions Ultimately, this episode asks whether longevity medicine can become a credible part of healthcare without losing scientific and clinical rigor as the market scales. For Joanna, the path forward involves better education, clearer standards, measurable outcomes, collaboration and a more integrated approach to health that extends beyond the traditional doctor-patient relationship. Subscribe for weekly episodes exploring longevity science, preventative medicine, healthcare innovation and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
The $51M Bet to Make the Doctor Obsolete
2026/08/24
Sponsor: Longevity Investors Conference The Longevity Investors Conference brings together the scientists working at the root of aging, the clinicians translating research into practice, the founders building the next generation of longevity companies, and the investors deciding what gets funded next. The seventh edition takes place from 14 to 17 September 2026 at Le Grand Bellevue in Gstaad, Switzerland. Participation is limited and applications are reviewed individually. Click the link below to apply for LIC 2026. Link: https://www.longevityinvestors.ch/lic-2026 ---------- Guests: Max Marchione Founder & CEO of Superpower, Speaker at Longevity Investors Conference Gstaad 2026 LinkedIn and X: https://www.linkedin.com/in/maxmarchione/, https://x.com/maxmarchione Website: https://superpower.com/ ---------- What if the future of healthcare is not a better hospital, but a system designed to keep you out of one? Phil Newman sits down with Max Marchione, co-founder and CEO of Superpower, to explore his vision for a preventive health platform combining advanced diagnostics, longitudinal health data, wearables, AI and clinicians in one continuous system. Recorded as a Longevity Investors Conference special, the conversation examines why healthcare remains largely reactive and episodic, and what it would take to create an experience that continuously monitors health, connects biological signals and intervenes before problems become disease. Max explains how Superpower uses AI to examine data across blood tests, medical records and wearables, identifying patterns that may be difficult to uncover during a short medical appointment. They also discuss where human clinicians remain essential, particularly when decisions involve prescriptions, hormone therapy or other higher-risk interventions. The conversation explores the limitations of conventional blood-test reference ranges, the growing interest in peptides, including GLP-1 therapies and the controversial BPC-157, and why promising anecdotes must still be tested through rigorous clinical research. They also discuss Superpower’s direct-to-consumer and employer-funded models, the observational health dataset the company is building, the regulatory debate around right-to-try laws and Max’s much larger ambition to help create healthier cities. In this episode, you’ll learn: Why Max believes healthcare will become more preventive, continuous and software-driven.How AI could connect patterns across blood tests, wearables, medical records and reported symptoms.Why being within a “normal” blood-test range does not necessarily mean a result is optimal for long-term health.Where AI may support medical reasoning and why physicians remain responsible for important treatment decisions.How Superpower aims to make elements of high-cost concierge medicine accessible at a lower price.Why employers and insurers may have a financial incentive to invest in preventive healthcare.Why peptides could become an increasingly important medical modality, and where the evidence remains uncertain.How repeated testing, treatment data and symptom tracking could contribute to longitudinal observational research.What right-to-try laws could mean for medical autonomy, regulation and clinical innovation.What a health-first city might look like and why infrastructure, community and culture matter as much as policy. If you want to understand how AI, continuous diagnostics and longitudinal data could shift healthcare from episodic treatment toward proactive health management, this episode connects an ambitious technological vision with the clinical, commercial and regulatory realities of building a new healthcare system. Subscribe for weekly episodes exploring longevity science, preventive medicine and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
From K-Beauty to K-Longevity: South Korea’s New Health Model | Longevity News Roundup - Week 34, 2026
2026/08/21
In this week’s Longevity News Roundup, Phil Newman examines South Korea’s emerging health tourism model, Network Bio’s biological data platform, Utah’s growing longevity economy, GenBio AI’s virtual cell system, and Longevica’s push toward clinical translation. South Korea is attracting international patients with comprehensive preventive screening that can combine bloodwork, imaging, cardiovascular assessment, cancer screening and physician consultation in a highly compressed pathway.Network Bio has launched with $50 million in financing, using patient tissue, paired blood samples, molecular data and longitudinal outcomes to search for biological signals that transfer across diseases. Utah is building a different kind of longevity hub, with physician-led practices, fitness and recovery businesses, diagnostics, consumer health brands and wellness companies clustering around Salt Lake City and Park City. GenBio AI has launched AIDO Cell, a stateful virtual cell designed to connect DNA, RNA, proteins and cellular behavior while retaining the effects of previous interventions. Longevica Therapeutics has appointed Dr. Prasun Mishra as CEO, bringing Genentech, Roche and NIH experience into a company attempting to move large-scale mammalian longevity research toward drug development. ---------- News & References: ‘The barriers aren’t clinical, they’re structural’ → https://longevity.technology/news/the-barriers-arent-clinical-theyre-structural/Network Bio launches with $50m for biological AI → https://longevity.technology/news/network-bio-launches-with-50m-for-biological-ai/Utah is building America’s longevity capital → https://longevity.technology/news/utah-is-building-americas-longevity-capital/Can AI put the cell back together? → https://longevity.technology/news/can-ai-put-the-cell-back-together/Longevica appoints ex-Genentech biotech veteran as CEO → https://longevity.technology/news/longevica-appoints-ex-genentech-biotech-veteran-as-ceo/ ---------- Host: Phil Newman: https://qrco.de/bgXpNY

Podcast reviews

Read Longevity.Technology UNLOCKED podcast reviews


5 out of 5
4 reviews

Podcast sponsorship advertising

Start advertising on Longevity.Technology UNLOCKED relevant audience podcasts


What do you want to promote?